ALVO
Price
$8.79
Change
+$0.77 (+9.60%)
Updated
Aug 18, 03:02 PM (EDT)
Capitalization
2.5B
86 days until earnings call
CLSH
Price
$0.04
Change
-$0.00 (-0.00%)
Updated
Jul 3 closing price
Capitalization
5.94M
Interact to see
Advertisement

ALVO vs CLSH

Header iconALVO vs CLSH Comparison
Open Charts ALVO vs CLSHBanner chart's image
Alvotech
Price$8.79
Change+$0.77 (+9.60%)
Volume$1.05K
Capitalization2.5B
CLS Holdings USA
Price$0.04
Change-$0.00 (-0.00%)
Volume$26.23K
Capitalization5.94M
ALVO vs CLSH Comparison Chart in %
Loading...
ALVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLSH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALVO vs. CLSH commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALVO is a Hold and CLSH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (ALVO: $8.02 vs. CLSH: $0.04)
Brand notoriety: ALVO and CLSH are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALVO: 189% vs. CLSH: 66%
Market capitalization -- ALVO: $2.5B vs. CLSH: $5.94M
ALVO [@Pharmaceuticals: Generic] is valued at $2.5B. CLSH’s [@Pharmaceuticals: Generic] market capitalization is $5.94M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALVO’s FA Score shows that 1 FA rating(s) are green whileCLSH’s FA Score has 1 green FA rating(s).

  • ALVO’s FA Score: 1 green, 4 red.
  • CLSH’s FA Score: 1 green, 4 red.
According to our system of comparison, CLSH is a better buy in the long-term than ALVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALVO’s TA Score shows that 3 TA indicator(s) are bullish while CLSH’s TA Score has 1 bullish TA indicator(s).

  • ALVO’s TA Score: 3 bullish, 6 bearish.
  • CLSH’s TA Score: 1 bullish, 4 bearish.
According to our system of comparison, ALVO is a better buy in the short-term than CLSH.

Price Growth

ALVO (@Pharmaceuticals: Generic) experienced а -5.14% price change this week, while CLSH (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.59%. For the same industry, the average monthly price growth was +9.90%, and the average quarterly price growth was +76.92%.

Reported Earning Dates

ALVO is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.59% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALVO($2.5B) has a higher market cap than CLSH($5.94M). ALVO has higher P/E ratio than CLSH: ALVO (34.89) vs CLSH (3.60). CLSH YTD gains are higher at: 18.197 vs. ALVO (-39.342). ALVO has higher annual earnings (EBITDA): 139M vs. CLSH (4.72M). ALVO has more cash in the bank: 38.5M vs. CLSH (221K). CLSH has less debt than ALVO: CLSH (4.84M) vs ALVO (1.23B). ALVO has higher revenues than CLSH: ALVO (586M) vs CLSH (17.5M).
ALVOCLSHALVO / CLSH
Capitalization2.5B5.94M42,111%
EBITDA139M4.72M2,945%
Gain YTD-39.34218.197-216%
P/E Ratio34.893.60968%
Revenue586M17.5M3,349%
Total Cash38.5M221K17,421%
Total Debt1.23B4.84M25,341%
FUNDAMENTALS RATINGS
CLSH: Fundamental Ratings
CLSH
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
52
P/E GROWTH RATING
1..100
21
SEASONALITY SCORE
1..100
34

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ALVOCLSH
RSI
ODDS (%)
Bullish Trend 6 days ago
70%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
54%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
47%
N/A
MACD
ODDS (%)
Bearish Trend 4 days ago
53%
Bearish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
63%
Bullish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
65%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 6 days ago
62%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
68%
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
52%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
68%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ALVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLSH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SGFFX52.03-0.01
-0.02%
Sparrow Growth A
PAEAX21.65-0.02
-0.09%
Putnam Dynamic Asset Allocation Gr A
NBHAX14.68-0.03
-0.20%
Neuberger Berman Equity Income A
OAZMX163.39-0.32
-0.20%
Oakmark R6
MDDLX10.57-0.06
-0.56%
MassMutual Diversified Value Adm

ALVO and

Correlation & Price change

A.I.dvisor tells us that ALVO and EBS have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALVO and EBS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALVO
1D Price
Change %
ALVO100%
-5.31%
EBS - ALVO
32%
Poorly correlated
+0.23%
VTRS - ALVO
26%
Poorly correlated
-0.75%
PAHC - ALVO
24%
Poorly correlated
+0.33%
CRON - ALVO
21%
Poorly correlated
-5.95%
TLRY - ALVO
21%
Poorly correlated
-12.71%
More

CLSH and

Correlation & Price change

A.I.dvisor tells us that CLSH and TSNDF have been poorly correlated (+15% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLSH and TSNDF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLSH
1D Price
Change %
CLSH100%
N/A
TSNDF - CLSH
15%
Poorly correlated
+1.10%
SHPH - CLSH
8%
Poorly correlated
-5.14%
EAPIF - CLSH
7%
Poorly correlated
N/A
ALVO - CLSH
6%
Poorly correlated
-5.31%
CNADF - CLSH
6%
Poorly correlated
N/A
More